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Abstract
Immunoglobulin G (IgG) antibodies that trap viruses in cervicovaginal mucus (CVM) via 
adhesive interactions between IgG-Fc and mucins have recently emerged as a promising strategy 
to block vaginally transmitted infections. The array of IgG bound to a virus particle appears to trap 
the virus by making multiple weak affinity bonds to the fibrous mucins that form the mucus gel. 
However, the antibody characteristics that maximize virus trapping and minimize viral infectivity 
remain poorly understood. Toward this goal, we developed a mathematical model that takes into 
account physiologically relevant spatial dimensions and time scales, binding, and unbinding rates 
between IgG and virions and between IgG and mucins, as well as the respective diffusivities of 
virions and IgG in semen and CVM. We then systematically explored the IgG–antigen and IgG–
mucin binding and unbinding rates that minimize the flux of infectious HIV arriving at the vaginal 
epithelium. Surprisingly, contrary to common intuition that infectivity would drop monotonically 
with increasing affinities between IgG and HIV, and between IgG and mucins, our model suggests 
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maximal trapping of HIV and minimal flux of HIV to the epithelium are achieved with IgG 
molecules that exhibit (i) rapid antigen binding (high kon) rather than very slow unbinding (low 
koff), that is, high-affinity binding to the virion, and (ii) relatively weak affinity with mucins. 
These results provide important insights into the design of more potent “mucotrapping” IgG for 
enhanced protection against vaginally transmitted infections. The model is adaptable to other 
pathogens, mucosal barriers, geometries, and kinetic and diffusional effects, providing a tool for 
hypothesis testing and producing quantitative insights into the dynamics of immune-mediated 
protection.
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Antibodies (Abs) produced by our immune system are found in abundant quantities in both 
blood and mucosal secretions and serve as key molecules that help regulate numerous 
complex defense mechanisms against foreign pathogens.1 For example, Abs can directly 
block contact between viruses and target cells, a process known as neutralization.2 Abs can 
also facilitate other protective functions, such as ingestion and destruction of the pathogens 
(opsonization) or infected cells (antibody-dependent cellular cytotoxicity, or ADCC) by 
specialized immune cells, as well as activation of a cascade of enzymes that lead to direct 
lysis of the pathogen membrane (complement).3 These various protective mechanisms most 
certainly contribute to the robust protection observed with topically delivered Abs against 
mucosally transmitted infections in a multitude of animal studies.4
In the female reproductive tract, immunoglobulin G (IgG) is the predominant Ab secreted 
into cervicovaginal mucus (CVM) coating the vaginal epithelium,5 yet its role in protection 
against vaginal infections is not yet well understood. CVM is composed primarily of a 
heterogeneous mesh network of mucin fibers with low viscosity fluid-filled pores, most of 
which are larger than the majority of viruses.6 Indeed, HIV virions are capable of diffusing 
nearly unimpeded through the mucus gel.7 Noting the abundance of Abs produced and 
secreted by the immune system into mucus secretions, we hypothesized that virus-specific 
IgG may work in tandem with the mucin mesh to prevent infections. We recently showed 
that IgG can indeed trap viruses in CVM, thereby facilitating an additional and highly potent 
mechanism of immune protection.5c Interestingly, the diffusivity of IgG in mucus is only 
slowed ~10–20% compared to in buffer;8 hence, individual IgG molecules must make only 
weak and transient bonds with mucins and thus were previously thought incapable of 
effectively trapping viruses in mucus gels. Nevertheless, as IgG accumulates on the virus 
surface, the array of virion-bound IgG can collectively form multiple weak Ab–mucin bonds 
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between the virion and CVM, thereby generating sufficient avidity to slow or even 
immobilize individual virions in mucus akin to multiple weak links formed by a Velcro 
patch. Trapping viruses in mucus not only reduces the flux of virus reaching target cells in 
the vaginal epithelium, but trapped viruses are also quickly eliminated along with natural 
mucus clearance mechanisms, as evident by protection against vaginal herpes transmission 
using a non-neutralizing monoclonal IgG.5c
Many viruses, including HIV, can rapidly diffuse through mucus gels under physiological 
conditions, limiting the window of opportunity for Abs to accumulate on the virus surface 
before the virus reaches and infects the underlying vaginal epithelium.9 The extent to which 
IgG can hinder the diffusion of viruses in mucus, and consequently the potency of protection 
based on IgG-mediated trapping of viruses, is thus critically dependent on whether virus-
specific IgG, topically delivered or elicited by vaccine or prior infection, can accumulate 
rapidly enough on a virion and impart sufficient binding avidity between the virion and 
mucus to trap the virus before it can reach the underlying cells. We are interested in 
developing potent “muco-trapping” IgG (i.e., that enables effective trapping with fewer 
virion-bound IgG) not only because this would (i) reduce the dose of IgG needed for passive 
immunization of the vagina but also because this would (ii) likely improve protection 
against viruses, such as HIV, that have only a small number of antigens on their surface.
Our aim quickly posed a conundrum: although fewer virus-bound IgGs would be needed to 
trap a virus if each bound IgG binds more tightly to mucins, high IgG affinity to mucins 
would reduce or even prevent the diffusive mobility of IgG in the mucus gel. Because the 
Smoluchowski encounter rate between two diffusive species is proportional to the sum of 
their diffusivities, mucin-associated IgG would therefore have markedly reduced encounters 
with virions and, by definition, exhibit lower rates of binding to viral antigens. The IgG–
mucin and IgG–antigen affinities and actual binding/unbinding rates that maximize viral 
trapping and protection will depend on specific characteristics of the target virus, such as its 
diffusivity in mucus and surface antigen density.
Because an empirical, experimental determination of these numerous parameters and their 
relative contributions to trapping and protection remains exceedingly challenging, we turned 
to mathematical modeling to better understand the subtle interplay between the various 
kinetic and diffusive processes among IgG, virions, and CVM during vaginal transmission 
of sexually transmitted viruses. Specifically, we consider CVM containing a specific 
concentration of antigen-specific IgGs that possess tunable binding and unbinding kinetics 
to mucins in CVM subjected to introduction of virus-laden semen (Figure 1). With a 
mathematical model, starting from the moment of viral deposition in the female reproductive 
tract, we can model the subsequent codiffusion of virions and IgG as well as the binding and 
unbinding kinetics among IgG molecules, viruses, and mucins and freely explore the vast 
parameter space in the context of physiologically relevant spatial dimensions and time 
scales. As a proof-of-concept, we focused on HIV, given the great need for alternative 
strategies to prevent vaginal HIV transmission; indeed, passive immunization has recently 
garnered attention as a promising approach for HIV prophylaxis.10 In turn, the model allows 
us to explore whether, and the extent to which, tuning IgG–mucin affinity can facilitate 
improved protection against vaginal HIV infection. In doing so, we report that the model 
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suggests a “sweet spot” in the characteristics of IgG that maximize trapping and minimize 
infectious flux of HIV to the vaginal epithelium.
RESULTS
Incorporating Mucin-Binding Kinetics into Previous Models for HIV Penetration of Ab-
Laden CVM
We have previously modeled the diffusion of HIV through CVM by combining a stochastic/
deterministic hybrid model for the one-dimensional Brownian movement of individual HIV 
virions together with a continuum model that describes the average local concentration of 
broadly neutralizing monoclonal IgG in CVM.11 That model allowed us to show that a 
multitude of weak bonds between virion-bound IgG and mucins alone, defined by the ratios 
of IgG diffusion in mucus versus buffer (α) in the range of 0.8–0.9, is sufficient to 
immobilize the vast majority of HIV near the semen/CVM interface. Nevertheless, to further 
explore the IgG trapping potency across the full range of IgG–mucin affinity, it was 
necessary to incorporate additional complexity into the model. First, when modeling IgG 
that binds more tightly to mucins, we made the assumption that the probability of a 
successful bond between an IgG molecule and the corresponding viral antigen is directly 
proportional to the overall collision frequencies between the two bodies, which can be 
described by the classical Smoluchowski principle.12 Because an IgG bound to mucins will 
possess a far reduced range of motion relative to that of a free, unbound IgG molecule, the 
bound IgG should possess a reduced kon rate, denoted kon′, proportional to the reduction in 
collision frequency with viral antigen, which in turn can be approximated by the ratios of the 
diffusivity of IgG versus mucins in CVM. Although the diffusivity of individual mucins in 
CVM remains unknown, we have previously shown that CVM is composed of heavily 
bundled mucins that likely reflect an exceedingly limited range of motion for individual 
mucins.6 We thus made a very conservative estimate that an IgG bound to mucin will 
possess a 30-fold reduced kon rate compared to individual free IgG (i.e., kon′ = kon/30), 
which roughly equates to assuming the range of motion of mucins to match that for 
individual HIV virions. Although obviously an overconservative assumption, further 
reduction in kon′ does not meaningfully affect estimates generated by our model (Figure S4).
A second important detail we incorporated into our model is the kinetics of IgG binding to 
and unbinding from mucins, which we termed mon and moff, respectively. Experimentally, 
mon and moff appear to be extremely transient and difficult to measure individually8 (see also 
the Supporting Information). Instead, IgG–mucin affinity is inherently reflected by the 
diffusion coefficients of IgG in CVM versus in buffer, which we denote α. α reflects the 
fraction of bound versus unbound IgG at any moment in time and is equivalent to the ratio 
moff/(moff + [M]mon) at steady state. Assuming IgG binding to its antigen does not increase 
its affinity to mucins, the rates with which individual IgG can bind to mucins must be far 
faster than the rate of virion-associated IgG binding to mucins. We thus introduced a 
correction factor of ~30 for the mucin-association kinetics for virion-bound IgG, which is 
equivalent to the difference in diffusivities of HIV versus IgG in CVM. This correction was 
necessary to ensure we do not overestimate the trapping potency of viruses.
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As a first step toward understanding how IgG–mucin affinity can affect trapping potency, 
we modeled the probability and duration of HIV–IgG complexes associating with mucins in 
CVM containing 1 µg/mL NIH45-46 with varying IgG–mucin affinity. Naturally, HIV with 
surface IgG possessing no affinity to mucins, defined by α = 1, never binds to mucins, and 
the HIV–IgG complex undergoes free diffusion for the entire duration (Figure 2A). When 
IgG–mucin affinity is slightly increased such that individual IgGs associate with mucins ~5 
and 10% of the time (i.e., α = 0.95 and 0.9, respectively), the fraction of time an HIV–IgG 
complex spends freely diffusing in mucus begins to decrease, with a corresponding increase 
in the fraction of time spent associated with mucins (Figure 2B,C). Interestingly, the fraction 
of time the HIV–IgG complex associates with mucins appears to peak between α = 0.1 and 
0.25 (Figure 2D–F). This is attributed to the facts that (i) increased IgG–mucin affinity 
markedly reduces the fraction of NIH45-46 that can freely diffuse and readily bind to HIV, 
including IgG that diffuses from CVM into the semen layer and binds to HIV virions before 
they enter the CVM layer (Figure S2); and (ii) mucin-associated IgG captures HIV with far 
lower efficiency (i.e., reduced kon′ vs kon). These two factors together increase the number 
of HIV virions with no bound IgG. With further increases of mucin affinity to α = 0.01, the 
amount of HIV free of bound IgG dominates relative to HIV–IgG complexes, and most HIV 
again undergoes Brownian motion in CVM (Figure 2G).
Influence of IgG–Mucin Affinity on Maximizing Trapping Potency and Vaginal Protection
We next quantified how the probability of HIV–mucin association affects the fraction of 
HIV that can penetrate CVM and reach the underlying vaginal epithelium and the 
corresponding reduction in infectivity based on the decrease in HIV–Env free of bound IgG 
on those virions.9 In good agreement with the estimate of the fraction of time spent 
associated with mucins, the maximum reduction in HIV flux reaching the vaginal epithelium 
peaks at IgG–mucin affinities corresponding to α = 0.25 (Figure 3A). At 5 and 10 µg/mL 
NIH45-46 initially present in CVM and an IgG–mucin affinity equivalent to α = 0.25, only 
~3 and ~0.3% of the HIV viral load in semen, respectively, are predicted to reach the 
vaginal epithelium over the first 2 h post-ejaculation, equating to 10–100-fold reduced flux 
compared to the estimated ~30% of HIV load over the same duration in the absence of IgG–
mucin affinity (Figure 3A). Under this scenario, each HIV virion on average possesses ~2 
bound IgGs (Figure 3B), and the overall infectivity is reduced by 86–94% (i.e., ~7–16-fold) 
compared to IgG without affinity to mucins (Figure 3C,D). Note that the reduction in 
infectivity is less than the reduction in the flux of HIV viruses because NIH45-46 without 
affinity to mucins can still neutralize the virus.
When IgG–mucin affinity is further increased (i.e., lower α), the fraction of HIV reaching 
the vaginal epithelium begins to increase. Furthermore, there are also substantially fewer 
IgGs bound to HIV–Env on virions that reach the vaginal epithelium. Indeed, when α drops 
below 0.1, on average <1 IgG molecule is bound to each virion over the entire population of 
HIV virions, which implies that there must be HIV virions without any bound IgG (Figure 
3B). As a result, the infectivity of HIV may actually be greater for hypothetical NIH45-46 
that can bind tightly to mucins than if NIH45-46 possessed no mucin affinity at all (Figure 
3C,D).
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To begin to understand how to engineer more potent HIV-trapping IgG, we evaluated the 
relative impact of the rate of IgG binding to the virus surface compared to IgG–mucin 
affinity. The rate of IgG binding to HIV is the product of both the local IgG concentration 
and kon, the binding kinetic constant: a doubling of IgG kon has the same impact on IgG 
binding to HIV as doubling the IgG concentration. The reduction of HIV flux arriving at the 
vaginal epithelium and the reduction in mean number of NIH45-46-free Env proteins on 
HIV that reached the vaginal epithelium were sensitive to both IgG–antigen binding rate and 
IgG–mucin affinity (Figure 4). When IgG–mucin affinity was increased, the amount of 
initial NIH45-46 in CVM needed to reduce the flux of viruses arriving at the vaginal 
epithelium by 50% decreased from 5 to 50 µg/mL for α = 0.8–0.9 (this IgG–mucin affinity 
is within the range of what was previously measured for IgG in CVM) to <1 µg/mL when α 
= 0.25 (Figure 4A). Similarly, the amount of NIH45-46 needed to reduce the mean number 
of NIH45-46-free Env proteins on HIV by 80% decreased from 26 µg/mL for α = 0.8 to 3 
µg/mL for α = 0.25 (Figure 4D). Overall, the amount of NIH45-46 needed to reduce 
infectivity by 90% decreased from 7 µg/mL when α = 1 to 2 µg/mL when α = 0.25 (Figure 
4C).
Influence of IgG–Antigen Binding Affinity on Maximizing Trapping Potency and Vaginal 
Protection
A longstanding assumption for neutralizing IgG against HIV and other viruses is that higher 
binding affinity between IgG and viral antigen facilitates more potent protection. However, 
it is important to note that high-affinity IgGs are typically identified and selected on the 
basis of neutralization assays in the absence of mucus coatings and with some incubation 
time between virus and IgG prior to exposure of the virus to target cells. Thus, we sought to 
quantitatively evaluate whether a high antigen–IgG affinity that typically maximizes 
neutralization potency in vitro would also be maximally protective against mucosal HIV 
transmission in our model.
Interestingly, we found that the antigen-unbinding rate koff generally possessed only a very 
minor effect on increasing the fraction of HIV load that is trapped in mucus or facilitating 
more effective protection, especially when the IgG concentration or the kon rate is low 
(Figure 5A). For example, at 1 µg/mL of IgG with kon of 1.5 × 104 M−1 s−1 (kon[Ab] = 10−4 
s−1), improvements of koff from 10−3 s−1 to 10−4 s−1 reduced the HIV flux arriving the 
vaginal epithelium by only 1.6%, and a further improvement from 10−4 s−1 to 10−5 s−1 
essentially resulted in no appreciable difference in reduction of flux (Figure 5A). This is 
similarly reflected by the minimal change in the infectivity of the viruses relative to IgG 
with no mucin affinity from 100% with koff = 10−3 s−1 to 96% with koff = 10−4 s−1 to finally 
92% with koff = 10−5 s−1 (Figure 5C,D). The lack of impact by koff is directly attributed to 
the exceedingly limited number of IgG molecules that can accumulate on the surface of HIV 
either when IgG is present at low to modest concentrations or when IgG possesses 
inadequate binding kinetics (Figure 5B); slower unbinding kinetics simply cannot enhance 
HIV trapping in mucus or neutralization when few or no IgGs are bound to HIV in the first 
place.
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In contrast to koff, the IgG–antigen binding rate kon plays a far more critical role in effective 
mucosal protection. Because the rate of IgG accumulation on the virion surface is the 
product of the IgG concentration and kon, increasing IgG kon by definition would have the 
same magnitude of impact as increasing IgG concentration. In other words, a 10-fold faster 
kon would reduce the fraction of HIV reaching the vaginal epithelium and overall infectivity 
to the same extent as increasing the total HIV-binding IgG in CVM by 10-fold (Figure 5A), 
because both would result in the same increase in the number of IgG bound to HIV before 
the virions can reach the vaginal epithelium. Our current finding on the relative importance 
of kon versus koff is consistent with an earlier investigation that simply evaluated the kinetics 
of neutralization, which did not take into account IgG–mucin interactions.11 Incorporating 
IgG–mucin affinity appears to amplify the difference, likely because rapidly binding IgG 
can protect by either trapping or neutralization, and viruses slowed by IgG–mucin 
interactions will also be more completely neutralized prior to reaching target cells 
underlying the vaginal epithelium.
DISCUSSION
A hallmark of HIV is its exceptionally high mutation rate, which enables the virus to readily 
escape antibodies generated by the immune system and prevents the host from mounting a 
protective immune response. Comprehensive studies of elite controllers—the rare 
individuals who can maintain undetectable viral load without antiretroviral therapy—led to 
the discovery and cloning of monoclonal antibodies that can broadly neutralize the vast 
majority of HIV strains. These broadly neutralizing antibodies (bnAbs) were thought to 
provide a template for the development of an HIV vaccine. Unfortunately, HIV vaccines, 
including those that can block vaginal transmission of HIV, remain elusive to date, for at 
least two reasons. First, bnAbs are typically highly somatically mutated, and vaccines may 
not be able to elicit the extent of somatic hypermutation needed in most individuals to 
generate the desirable bnAbs. Second, many HIV vaccine candidates are based on DNA or 
subunit proteins rather than attenuated virus; the durability of antibody response from 
subunit vaccines is generally shorter than that of vaccines based on attenuated virus, and the 
level of antibody titers induced in the vagina may be inadequate to block vaginal HIV 
transmission.
To overcome these challenges, a recently emerged strategy is to passively immunize the 
vagina via sustained delivery of bnAbs.10b, 13 By dosing the bnAbs directly into the vagina, 
this strategy not only bypasses the limitations of somatic hypermutation but also ensures 
protective levels of bnAbs are present in the vagina to block HIV transmission. Despite 
these important advantages, a critical shortcoming for passive immunization is the relatively 
high cost of maintaining protective levels of antibody in the body compared to vaccination. 
Much effort has been spent on reducing the costs of antibody production, such as the 
production of antibodies in plants,14 as well as cheaper and more efficient methods of 
purifying antibodies.15 Here, we introduce a novel and completely distinct approach—based 
on tuning IgG–mucin interactions—that could markedly reduce the dose of bnAbs needed to 
block vaginal HIV transmission. The majority of bnAbs against HIV appear to possess kon 
in the range of 104 M s−1, which we previously estimated may require concentrations in 
excess of 5–10 µg/mL to facilitate effective protection. Although we predict enhanced 
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vaginal protection can be accomplished with both increasing kon and optimizing IgG–mucin 
affinity, bnAbs generally bind to a very unique epitope on HIV-Env that makes it unlikely 
that kon can be substantially improved without compromising binding affinity (i.e., resulting 
in higher koff). In contrast, simply by tuning the interactions between IgG–Fc and mucins, 
we can potentially reduce the required dose of bnAb for effective protection by 3.5-fold or 
more without jeopardizing the broad antigen coverage of bnAb. Optimizing IgG–Fc 
interactions with mucins thus offers a promising strategy to markedly reduce the costs for 
effective passive immunization of the vagina. The convergence of these various approaches 
may synergistically drive down costs and make passive immune protection against HIV 
cost-effective even in resource-poor settings.
Surprisingly, our model suggests that high-affinity IgG–mucin interactions are unlikely to 
enhance protection. Instead, the ideal IgG–mucin affinity that maximizes protection in our 
model (α ~ 0.25) is comparable to the mucin affinity previously measured for IgM 
molecules.8 It is also worth noting that IgM, due to its pentameric structure, has 10 Fab arms 
compared to 2 Fab arms for each IgG and hence can bind to its antigenic target and 
accumulate on the surface of virions with exceptional speed even if each Fab possesses 
relatively poor affinity compared to a fully affinity-matured IgG. Thus, an IgM molecule 
appears to simultaneously satisfy both of the design requirements we have identified in this 
study—rapid kon and modest mucin affinity. Indeed, we recently found that IgM that binds 
HIV-sized nanoparticles exhibited greater mucotrapping potency than corresponding IgG 
(Henry et al., submitted for publication). IgM is the first antibody isotype produced by our 
immune system and appears early in the course of an infection. Virus-specific IgM also 
usually reappears upon re-infection. Although speculative, our study raises the hypothesis 
that an evolved effector function of IgM may be to quickly begin purging a new pathogen 
from mucosal surfaces that likely represent the initial site of infection early in the course of 
infection, and thereby minimize the viral titers that can enter the systemic circulation.
As discussed above, it is unlikely that we can markedly improve the kon for bnAbs without 
potentially compromising their broad antigenic coverage. An alternative method to enhance 
the overall rate of IgG accumulating on the viral surface at mucosal secretions is to include 
IgG targeting other viral epitopes, including potentially non-neutralizing epitopes, because 
trapping virions in mucus requires only binding and not necessarily neutralizing IgG. It is 
important to note that the immune system typically generates a polyclonal Ab response 
against diverse epitopes, rather than solely a neutralizing Ab response against a single viral 
epitope. Indeed, many of the naturally produced IgG against HIV found in HIV patients 
associate with either the lipid membrane of HIV virions, or other parts of the gp120 site on 
the Env spike not directly involved in HIV infection of immune cells.16 Likewise, virtually 
all of the IgGs detected in the moderately successful RV144 trial were non-neutralizing.17 
Such a polyclonal response would likely result in a substantially faster rate of Ab 
accumulation than with an individual monoclonal IgG. Thus, codelivery of multiple IgGs to 
enhance passive immune protection of the vagina, or inclusion of multiple immunogens 
(including non-neutralizing epitopes) in vaccine formulations, would both harness the same 
strategy our immune system has evolved to fend off foreign pathogens.
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Although often under-appreciated, CVM represents the first line of defense against sexually 
transmitted infections in the female reproductive tract. In addition to minimizing trauma to 
the vaginal epithelium upon coital stirring, the presence of the CVM layer also prevents 
virions in semen from immediately contacting the vaginal epithelium upon ejaculation and 
directly reduces the virion flux and total viral load in semen that can reach target cells over 
time. Reinforcing the CVM barrier against sexually transmitted viral infections using virus-
specific Abs that trap viruses in mucus is likely an important mechanism of the vaginal 
mucosal defense, but one that continues to be largely under-appreciated and under-explored. 
We expect that the combination of quantitative, predictive models with experimental 
validation will enable development of improved passive immunization as well as 
vaccination methods that harness the mucus barrier to reinforce mucosal defense against 
HIV and other sexually transmitted infections.
MATERIALS AND METHODS
Model Parameters for Vaginal Transmission of Cell-free HIV
In the female reproductive tract, mucus flows into the vagina from the cervical os, spreads 
over the vaginal epithelium, and is eventually cleared through the introitus. In this process, 
the thickness of the CVM layer likely varies within the vagina, with the thickest layer likely 
to be at the cervical os and vagina fornices, the thinnest near the introitus, and possibly 
substantial variations throughout. In the absence of experimental measurements of the 
thickness of the mucus layer coating the human vagina, we made the assumption that CVM 
approximately evenly covers the entire vaginal epithelial surface, due to spreading by 
repeated coital motion. We estimated the CVM layer thickness by dividing the volume of 
mucus (~750 µL; range typically between 500 µL and 2 mL) with the approximate surface 
area of the vaginal lumen (145 cm2;18 Table 1), which results in a thickness of roughly L = 
50 µm. Our estimate of approximate mucus volume is based on the volume that may be 
collected by repeated use of a menstrual collection device, the Instead Softcup, which we 
have utilized in prior studies.5c,6,7a,b,19 Although the Softcup is intended to be placed over 
the cervical os during menses, in our studies, donors typically insert the Softcup for only 5–
10 s. Due to the limited duration of insertion, the mucus we collect reflects predominantly 
mucus overlaying the vaginal surface that was gathered on the SoftCup during the insertion/
extraction process, rather than mucus that flowed out of the cervical os and pooled onto the 
cup over many hours. This procedure allows us to obtain substantial volumes of mucus that 
contains the same microbial communities and densities as sampling by vaginal swabs.7b
Similar to previous studies,9,11,20 we modeled the diffusion of HIV (DHIV ~ 1.27 µm2/s11) 
from a virion-rich layer of semen (8.4 × 105 virions, the average viremia in semen of acutely 
infected males9,21 in an ejaculate volume of ~3.0 mL22) uniformly deposited on the luminal 
surface of the CVM layer. This results in a thickness of d = 200 µm for the semen layer. 
Neutralizing Abs (DAb ~ 40 µm2/s11) accumulate on HIV virions at rates depending on Ab–
antigen affinity, the number of available antigen sites on the virus surface, the local Ab 
concentration, and the diffusivity of the Abs in CVM. For a model monoclonal broadly 
neutralizing Ab against HIV, we focused on NIH45-46, which binds to the CD4 binding site 
of gp120 and whose binding affinities were previously described.23 The number of Env 
Wessler et al. Page 9













spikes N* on individual HIV virions is variable and was estimated to follow a negative 
binomial distribution with N* = 14 ± 7 (range 4–35) based on cryoelectron microscopy of 
HIV virions.24
Ab Binding to HIV Env Spikes
We assume each Env spike can bind up to three Abs without significant steric hindrance; 
thus, individual Abs at concentration u(z,t) can bind and unbind independently with rates kon 
and koff, and overall binding/unbinding rates depend on the number of unoccupied binding 
sites 3N* −n, where n is the number of bound Ab. However, because the diffusivity for a 
mucin-bound Ab ub(z,t) is reduced compared to free individual Ab, the Smoluchowski 
encounter rate, which describes the collision rate of two populations of spherical particles 
diffusing freely in three dimensions, implies that the binding rate for a mucin-bound Ab 
 to its antigen should be reduced proportionally to the difference in diffusivities of the 
Ab (DAb) and the virus (Dv); hence,  kon ≈ (1/30) kon. The Ab–virion 
binding rate equations can be summarized as
(1)
where (Ab) is an unbound Ab, (Ab)nZ(t) denotes a virion at Z(t) with n bound Ab, and 
superscript/subscript f and b denote free and bound terms, respectively. Individual Abs also 
bind and unbind to mucins at rates mon[M] and moff, where [M] is the effective 
concentration of Ab binding sites in the mucin network. In addition, virion-bound Abs may 
associate with mucins, effectively immobilizing the entire Ab–virion complex for the 
duration of the interaction.
HIV Diffusion through CVM
We developed two different methods to simulate HIV penetration across the vaginal mucus 
layer. In the first method, a stochastic particle simulation was used for virion diffusion, 
virion–Ab binding, and Ab–mucin interactions. Because the number of Abs is much larger 
than the number of virions, we utilized a diffusion partial differential equation (PDE) for the 
Ab concentration. Virion diffusion for a particle Z is given by the stochastic differential 
equation (SDE) dZ = (2D)1/2 dW, where W is Brownian motion and , 
where “free” indicates that all virion-bound Abs are free from mucin and “bound” indicates 
that at least one virion-bound Ab is associated with mucin. We assume Brownian diffusion 
of virions based on our previous findings that HIV and other viruses and nanoparticles can 
diffuse nearly unobstructed in CVM.5c,7a,b,19 Importantly, although we are measuring the 
rate of virus arriving the epithelium, an essentially 1D process, the actual simulated random 
walks are in 3D. Ab binding and unbinding to virus were simulated with a Poisson random 
variable with rates given by eq 1. Lastly, Ab–mucin interactions were simulated with 
Poisson random variables and rates dependent on the total number of virion-bound Abs and 
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those Abs currently interacting with mucins. Due to the great computational expense 
involved in simulating Ab–mucin interactions, particularly when mon[M] > moff, we 
computed lookup tables giving the distributions for the time that a virion spends freely 
diffusing and the time that a virion spends interacting with mucins (see the Supporting 
Information and Figure S1). The (random) time that a virion spends freely diffusing is given 
by the last time that none of the surface-bound Abs associate with mucin until the next time 
that at least one of its associated Abs binds to mucin. Similarly, the time that a virion spends 
interacting with mucins is given by the last time that at least one of the virion-bound Abs 
associates with mucin until the next time that none of the surface-bound Abs associate with 
mucin. We then sampled from these lookup tables whenever a virion’s state changes (freely 
diffusing or bound to mucin, binding or unbinding an Ab, crossing the semen/CVM 
interface). These methods were used to generate data presented in Figure 2.
The second simulation method consists of a reaction–diffusion PDE to capture the average 
behavior of the virus population. The virus population is represented by a vector , 
where the component Vn(z,t) represents the concentration of virus with n bound Abs. We 
previously introduced a parameter α = (moff/(moff + [M]mon)) to represent the fraction of 
time that Abs in CVM spend freely diffusing.11 Because Ab–mucin interactions likely occur 
at fast time scales,
and
In the limit mon, moff → ∞ (keeping moff/(moff + [M]mon) fixed), the stochastic model can 
thus be approximated by the reaction–diffusion system
where the diffusion tensor D is a diagonal tensor with entries Dv0, β1Dv0, …, β3N* Dv0 along 
the diagonal (the diffusion factors βi are determined below) for 0 < d < 50 and diagonal 
entries are all Dv0 for 50 < d < 250; ; and the reaction terms 
 and  have entries 
 and 
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 for n = 0, 1, …, 3N*, respectively, 
with χ denoting the indicator function.
Simultaneous Diffusion of HIV and Ab
We use a forward-time central-space scheme to model diffusion for both the virus and Ab 
populations in 3D, with reflecting boundary conditions at the semen/lumen interface, 
reflecting conditions for Ab and absorbing conditions for virus at the CVM/cell interface, 
and Fick’s law for the discontinuous diffusion coefficients at the semen/CVM interface. We 
assume that the number of Abs binding to virions is negligible compared to the overall Ab 
population, so there are no local depletion effects.
If each virion-bound IgG binds and unbinds to the mucin mesh independently, then the 
virion spends approximately a fraction αn of time with all its bound Abs simultaneously free 
from mucin. This yields a time-averaged diffusivity for the virion of Dvn = αnDv0 in CVM. 
One adjustment is made, however, to account for the lower diffusivity of a virion–Ab 
complex compared with an individual Ab. Similar to the adjustments on kon, we define mfirst 
= (1/30), so that initial Ab–mucin encounters occur at rate mfirstmon[M]. For subsequent 
interactions of virion-bound Abs with mucin, the rate may increase because the Ab–virus 
complex is already located in close proximity to a mucin molecule or may decrease due to 
the reduced diffusivity of the Ab–virus complex associated with mucins relative to a 
nonassociated Ab–virus complex. Due to the lack of empirical data in the literature, we 
assumed other Abs bound to the same virion with at least one Ab already associating with 
mucins will associate with mucins with the same mucin-binding kinetics as a free Ab 
molecule. To calculate the diffusion factors β1, β2, …, β3N*, we first neglect the factor mfirst 
and consider the total time freei that a virion with i bound Abs spends freely diffusing and 
the total time boundi that it spends bound to mucins up to a time T. Because the Abs are 
assumed to bind and unbind to mucin independently, limT→∞(freei/(freei + boundi)) = αi, 
and thus βi = (freei/mfirst)/(freei/mfirst + boundi) = αi/(αi + mfirst(1 − αi)).
The stochastic simulations and the reaction–diffusion simulations show excellent agreement, 
particularly at rapid mon[M] and moff. Indeed, for mon[M] = 101 s−1, the difference between 
stochastic simulations and the reaction–diffusion simulations is on average ~8.5% and 
decreases to an average of ~3.5% for mon[M] = 102 s−1 (Figure S3; see the Supporting 
Information for theoretical estimates of mon[M] and moff). Hence, we used the deterministic 
simulations except where noted. These methods were used to generate data presented in 
Figures 3A,B, 4A,B, and 5A,B.
Env Neutralization by Binding Abs
In addition to measuring reduction in the flux of viruses arriving at the epithelium, we also 
incorporated virus infectivity and extent of Ab neutralization in our analysis. Determining 
the number of Abs required to neutralize a given HIV remains an active area of research, 
due to the difficulty in simultaneously distinguishing the number of Abs necessary to 
neutralize a particular Env spike and the minimum number of Ab-free Env spikes necessary 
for HIV to successfully infect.27 It was previously proposed that the binding of a single Ab 
molecule to an Env spike appears to be sufficient to inactivate the infectivity associated with 
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that spike.28 The minimum number of Ab-free Env spikes and, consequently, the number of 
Env spikes that must be inactivated to neutralize a virion, remain more controversial. 
Estimates for minimum infectivity range from a single Ab-free Env spike28 to many.29 For 
our current model, we assume that each additional Ab binding to a previously unoccupied 
Env incrementally reduces the likelihood of infection, and we measure the overall reduction 
in infectivity by the reduction in number of unoccupied Env arriving at the vaginal 
epithelium over the first 2 h post-ejaculation. These methods were used to generate data 
presented in Figures 3C,D, 4C,D, and 5C,D.
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Refer to Web version on PubMed Central for supplementary material.
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Schematic of our model that captures the dynamics of HIV from seminal fluid diffusing 
across a cervicovaginal mucus (CVM) layer containing HIV-binding IgG to reach the 
underlying vaginal epithelium. To reduce infection, IgG must bind to HIV in sufficient 
quantities to neutralize or to trap the virions in mucus before HIV virions successfully 
penetrate CVM. Our model captures the tandem effects of IgG–antigen binding kinetics 
(kon, koff) as well as IgG–mucin interactions (mon, moff).
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Distribution of time HIV virions spend freely diffusing or associated with mucins in CVM 
containing 1 µg/mL NIH45-46 with different affinity to mucins, ranging from no affinity at 
α = 1 to very strong affinity at α = 0.001. To minimize bias toward virions with no surface-
bound IgG undergoing free diffusion, Abs are allowed to accumulate on HIV for 30 min 
first prior to measuring the time of free diffusion or association with mucins for the 
subsequent 90 min.
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Predicted trapping potency and protection by 5 and 10 µg/mL NIH45-46 with varying 
affinity to mucins as characterized by α: (A) predicted fraction of HIV load initially in 
semen that can diffuse across CVM containing NIH45-46 over the first 2 h post-deposition; 
(B) average number of NIH45-46 bound to HIV arriving at the vaginal epithelium (values 
<1 represent HIV virions that arrive at the vaginal epithelium without any bound 
NIH45-46); (C, D) extent of NIH45-46-mediated protection, as quantified by infectivity 
Wessler et al. Page 19













relative to (C) no NIH45-46 present in CVM or (D) the same amount of NIH45-46 present 
but without any affinity to mucins.
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Phase diagrams mapping the predicted trapping potency and protection as a function of 
NIH45-46 concentration in CVM and IgG affinity to mucins as characterized by α: (A) 
fraction of HIV load initially in semen that can diffuse across CVM containing NIH45-46 
over the first 2 h post-deposition; (B) average number of Ab-free Env trimers on HIV 
arriving at the vaginal epithelium; (C, D) extent of NIH45-46-mediated protection, as 
quantified by infectivity relative to (C) no NIH45-46 present in CVM or (D) the same 
amount of NIH45-46 present but without any affinity to mucins.
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Phase diagrams mapping the predicted trapping potency and protection as a function of 
NIH45-46 unbinding kinetics from HIV virions (koff) as well as accumulation kinetics on 
HIV virions, which is influenced by both the local NIH45-46 concentrations and the binding 
rate (kon): (A) fraction of HIV load initially in semen that can diffuse across CVM 
containing NIH45-46 over the first 2 h post-deposition; (B) average number of Ab-free Env 
trimers on HIV arriving at the vaginal epithelium; (C, D) extent of NIH45-46-mediated 
protection, as quantified by infectivity relative to (C) no NIH45-46 present in CVM or (D) 
the same amount of NIH45-46 present but without any affinity to mucins.
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Table 1
Parameters and Values Incorporated into the Model
parameter symbol value refs
HIV-1
  diffusivity in CVM Dv 1.27 µm2/sa 7a
  diffusivity in semen assume same as in CVM
  viral load in semen 8.4 × 105 copies/ejaculateb 21, 22
  no. of Env trimer spikes N* 14 ± 7 (SD) 24
IgG
  diffusivity in CVM DAb 40 µm2/s 8
  diffusivity in semen assume same as in CVM
  IgG concentration in CVM variable
  IgG–Env affinity kon, koff variable
  IgG–mucin affinity mon [M], moff variable
  ratio of DAb vs diffusivity in buffer α variable
vagina
  surface area of lumen SAvagina 145 cm2c 18a,b
  volume of luminal CVM VCVM ~750 µL 25
  thickness of CVM layer L 50 µmd
  volume of semen Vsemen ~3.0 mL 22
  thickness of semen layer d 200 µmd
a
The geometrically averaged Deff for HIV was previously measured to be 0.25 µm2/s, but with a substantial fraction of viruses exhibiting more 
rapid mobility. For the current analysis, we used 1.27 µm2/s, which represents the top 25th percentile of virus mobility; this is in reasonable 
agreement with a more recent study of HIV diffusion in genital secretions.7c
b
Estimated on the basis of a median semen volume of 3.0 mL22 and 2.8 × 105 HIV-1 RNA copies/mL, which represents the upper limit of HIV-1 
RNA copies/mL in seminal plasma from ref 21. This is in reasonable agreement with another report by Chakraboty et al., which estimated 5 × 105 
HIV-1 RNA copies/ejaculate, with a maximum of about 2 × 107 HIV-1 RNA copies/ejaculate.26
c
The mean surface area of the vagina in the native state was previously estimated to be ~ 90 cm2 by injection of vinyl polysiloxane casts vaginally. 
Alternatively, the surface area of vaginal lumen may also be inferred by the surface area of the erect penis (average ~200 cm2) assuming complete 
insertion into the vagina. We took the average from the two approaches.
d
CVM (L) and semen (d) thicknesses are estimated by VCVM/SAvagina and Vsemen/SAvagina, respectively.
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